Editas Medicine, Inc. - 8-K Filing
Editas Medicine receives approval to initiate first-in-human clinical trial for EDIT-401, an experimental gene editing therapy targeting hyperlipidemia. (Items: 7.01 Regulation FD Disclosure, 8.01 Other Events, 9.01 Financial Statements and Exhibits)
Tickers: $EDIT